STOCK TITAN

[Form 4] Lowe's Companies Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 filing for UnitedHealth Group (UNH) dated 07/02/2025 discloses routine quarterly equity compensation to non-employee director Paul R. Garcia.

  • Transactions (07/01/2025): 173 deferred stock units (immediately vested, must be held until board service ends) and 96 shares of common stock, both awarded at $0 cost.
  • Post-transaction ownership: 2,750 common shares held directly; 2,146 shares in a revocable trust; 45 and 55 shares in two additional trusts, for a total indirect holding of 2,246 shares.
  • No derivative securities were acquired or disposed of; the filing cites the awards as regular quarterly director compensation, not incentive-based or market purchases.

The filing is administrative in nature, with no impact on company operations, capital structure, or insider sentiment beyond customary board compensation.

Modulo 4 per UnitedHealth Group (UNH) datato 02/07/2025 rivela una consueta compensazione azionaria trimestrale al direttore non dipendente Paul R. Garcia.

  • Transazioni (01/07/2025): 173 unità di azioni differite (con maturazione immediata, da mantenere fino alla fine del mandato nel consiglio) e 96 azioni ordinarie, entrambe assegnate a costo zero.
  • Possesso post-transazione: 2.750 azioni ordinarie detenute direttamente; 2.146 azioni in un trust revocabile; 45 e 55 azioni in altri due trust, per un totale di 2.246 azioni detenute indirettamente.
  • Non sono stati acquisiti né ceduti titoli derivati; la dichiarazione indica che le assegnazioni sono compensi trimestrali regolari per il direttore, non basati su incentivi o acquisti di mercato.

La comunicazione ha carattere amministrativo, con nessun impatto sulle operazioni aziendali, sulla struttura del capitale o sul sentiment degli insider oltre la normale compensazione del consiglio.

Formulario 4 para UnitedHealth Group (UNH) fechado el 02/07/2025 revela una compensación trimestral rutinaria en acciones para el director no empleado Paul R. Garcia.

  • Transacciones (01/07/2025): 173 unidades de acciones diferidas (con vesting inmediato, que deben mantenerse hasta que finalice el servicio en la junta) y 96 acciones comunes, ambas otorgadas a costo cero.
  • Propiedad posterior a la transacción: 2.750 acciones comunes en propiedad directa; 2.146 acciones en un fideicomiso revocable; 45 y 55 acciones en dos fideicomisos adicionales, sumando un total de 2.246 acciones en propiedad indirecta.
  • No se adquirieron ni dispusieron valores derivados; la presentación indica que las concesiones son compensación trimestral regular para el director, no basadas en incentivos ni compras de mercado.

La presentación es de naturaleza administrativa, con sin impacto en las operaciones de la empresa, estructura de capital o sentimiento de los insiders más allá de la compensación habitual del consejo.

UnitedHealth Group (UNH)의 2025년 7월 2일자 Form 4 제출은 비임원 이사 Paul R. Garcia에 대한 정기 분기별 주식 보상을 공개합니다.

  • 거래 내역 (2025년 7월 1일): 즉시 권리 확정되며 이사회 임기 종료 시까지 보유해야 하는 173개의 이연 주식 단위와 96주의 보통주가 비용 없이 수여되었습니다.
  • 거래 후 소유 현황: 직접 보유한 보통주 2,750주; 취소 가능한 신탁에 2,146주; 추가 두 신탁에 각각 45주와 55주, 총 2,246주의 간접 보유.
  • 파생증권의 취득 또는 처분은 없었으며, 제출 서류는 해당 보상이 인센티브 기반이나 시장 구매가 아닌 정기적인 분기별 이사 보상임을 명시합니다.

이 제출은 행정적 성격이며, 회사 운영, 자본 구조 또는 내부자 심리에 관해 관례적인 이사회 보상을 넘어서는 영향은 없습니다.

Dépôt du formulaire 4 pour UnitedHealth Group (UNH) daté du 02/07/2025 révèle une rémunération trimestrielle habituelle en actions pour le directeur non salarié Paul R. Garcia.

  • Transactions (01/07/2025) : 173 unités d’actions différées (acquises immédiatement, à conserver jusqu’à la fin du mandat au conseil) et 96 actions ordinaires, toutes deux attribuées à coût nul.
  • Possession après transaction : 2 750 actions ordinaires détenues directement ; 2 146 actions dans une fiducie révocable ; 45 et 55 actions dans deux autres fiducies, totalisant 2 246 actions détenues indirectement.
  • Aucun titre dérivé n’a été acquis ou cédé ; le dépôt précise que ces attributions correspondent à la rémunération trimestrielle régulière du directeur, non basées sur des incitations ou des achats de marché.

Le dépôt est de nature administrative, sans impact sur les opérations de la société, la structure du capital ou le sentiment des initiés au-delà de la rémunération habituelle du conseil.

Formular 4 Einreichung für UnitedHealth Group (UNH) vom 02.07.2025 offenbart die routinemäßige vierteljährliche Aktienvergütung an den nicht geschäftsführenden Direktor Paul R. Garcia.

  • Transaktionen (01.07.2025): 173 aufgeschobene Aktieneinheiten (sofort unverfallbar, müssen bis zum Ende der Vorstandstätigkeit gehalten werden) und 96 Stammaktien, beide zu Nullkosten vergeben.
  • Besitz nach der Transaktion: 2.750 Stammaktien direkt gehalten; 2.146 Aktien in einem widerruflichen Trust; 45 und 55 Aktien in zwei weiteren Trusts, insgesamt 2.246 Aktien indirekt gehalten.
  • Es wurden keine Derivatwerte erworben oder veräußert; die Einreichung bezeichnet die Zuwendungen als reguläre vierteljährliche Direktorenvergütung, nicht als leistungsabhängige oder marktbasierte Käufe.

Die Einreichung ist administrativer Natur und hat keinen Einfluss auf die Unternehmensführung, Kapitalstruktur oder Insiderstimmung über die übliche Vorstandskomponente hinaus.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine director equity grant; neutral for valuation.

The reported acquisitions are standard board compensation—non-cash and immaterial relative to UNH’s 930 million shares outstanding. The director’s aggregate direct stake (≈0.0003%) remains negligible, offering no meaningful signal of insider conviction or strategy shift. No derivatives, sales, or large block moves were disclosed, and there is no indication of upcoming corporate events. Consequently, the filing should be viewed as housekeeping rather than a catalyst.

TL;DR: Confirms UNH’s standard board pay structure; no red flags.

The grant aligns with prevailing S&P 500 director pay practice of quarterly stock/DSU awards to foster alignment with shareholders. Mandatory deferral of DSUs until board departure supports long-term oversight. No unusual acceleration clauses or special awards appear, indicating consistent, transparent governance. The filing poses no governance concerns and is non-impactful to investors.

Modulo 4 per UnitedHealth Group (UNH) datato 02/07/2025 rivela una consueta compensazione azionaria trimestrale al direttore non dipendente Paul R. Garcia.

  • Transazioni (01/07/2025): 173 unità di azioni differite (con maturazione immediata, da mantenere fino alla fine del mandato nel consiglio) e 96 azioni ordinarie, entrambe assegnate a costo zero.
  • Possesso post-transazione: 2.750 azioni ordinarie detenute direttamente; 2.146 azioni in un trust revocabile; 45 e 55 azioni in altri due trust, per un totale di 2.246 azioni detenute indirettamente.
  • Non sono stati acquisiti né ceduti titoli derivati; la dichiarazione indica che le assegnazioni sono compensi trimestrali regolari per il direttore, non basati su incentivi o acquisti di mercato.

La comunicazione ha carattere amministrativo, con nessun impatto sulle operazioni aziendali, sulla struttura del capitale o sul sentiment degli insider oltre la normale compensazione del consiglio.

Formulario 4 para UnitedHealth Group (UNH) fechado el 02/07/2025 revela una compensación trimestral rutinaria en acciones para el director no empleado Paul R. Garcia.

  • Transacciones (01/07/2025): 173 unidades de acciones diferidas (con vesting inmediato, que deben mantenerse hasta que finalice el servicio en la junta) y 96 acciones comunes, ambas otorgadas a costo cero.
  • Propiedad posterior a la transacción: 2.750 acciones comunes en propiedad directa; 2.146 acciones en un fideicomiso revocable; 45 y 55 acciones en dos fideicomisos adicionales, sumando un total de 2.246 acciones en propiedad indirecta.
  • No se adquirieron ni dispusieron valores derivados; la presentación indica que las concesiones son compensación trimestral regular para el director, no basadas en incentivos ni compras de mercado.

La presentación es de naturaleza administrativa, con sin impacto en las operaciones de la empresa, estructura de capital o sentimiento de los insiders más allá de la compensación habitual del consejo.

UnitedHealth Group (UNH)의 2025년 7월 2일자 Form 4 제출은 비임원 이사 Paul R. Garcia에 대한 정기 분기별 주식 보상을 공개합니다.

  • 거래 내역 (2025년 7월 1일): 즉시 권리 확정되며 이사회 임기 종료 시까지 보유해야 하는 173개의 이연 주식 단위와 96주의 보통주가 비용 없이 수여되었습니다.
  • 거래 후 소유 현황: 직접 보유한 보통주 2,750주; 취소 가능한 신탁에 2,146주; 추가 두 신탁에 각각 45주와 55주, 총 2,246주의 간접 보유.
  • 파생증권의 취득 또는 처분은 없었으며, 제출 서류는 해당 보상이 인센티브 기반이나 시장 구매가 아닌 정기적인 분기별 이사 보상임을 명시합니다.

이 제출은 행정적 성격이며, 회사 운영, 자본 구조 또는 내부자 심리에 관해 관례적인 이사회 보상을 넘어서는 영향은 없습니다.

Dépôt du formulaire 4 pour UnitedHealth Group (UNH) daté du 02/07/2025 révèle une rémunération trimestrielle habituelle en actions pour le directeur non salarié Paul R. Garcia.

  • Transactions (01/07/2025) : 173 unités d’actions différées (acquises immédiatement, à conserver jusqu’à la fin du mandat au conseil) et 96 actions ordinaires, toutes deux attribuées à coût nul.
  • Possession après transaction : 2 750 actions ordinaires détenues directement ; 2 146 actions dans une fiducie révocable ; 45 et 55 actions dans deux autres fiducies, totalisant 2 246 actions détenues indirectement.
  • Aucun titre dérivé n’a été acquis ou cédé ; le dépôt précise que ces attributions correspondent à la rémunération trimestrielle régulière du directeur, non basées sur des incitations ou des achats de marché.

Le dépôt est de nature administrative, sans impact sur les opérations de la société, la structure du capital ou le sentiment des initiés au-delà de la rémunération habituelle du conseil.

Formular 4 Einreichung für UnitedHealth Group (UNH) vom 02.07.2025 offenbart die routinemäßige vierteljährliche Aktienvergütung an den nicht geschäftsführenden Direktor Paul R. Garcia.

  • Transaktionen (01.07.2025): 173 aufgeschobene Aktieneinheiten (sofort unverfallbar, müssen bis zum Ende der Vorstandstätigkeit gehalten werden) und 96 Stammaktien, beide zu Nullkosten vergeben.
  • Besitz nach der Transaktion: 2.750 Stammaktien direkt gehalten; 2.146 Aktien in einem widerruflichen Trust; 45 und 55 Aktien in zwei weiteren Trusts, insgesamt 2.246 Aktien indirekt gehalten.
  • Es wurden keine Derivatwerte erworben oder veräußert; die Einreichung bezeichnet die Zuwendungen als reguläre vierteljährliche Direktorenvergütung, nicht als leistungsabhängige oder marktbasierte Käufe.

Die Einreichung ist administrativer Natur und hat keinen Einfluss auf die Unternehmensführung, Kapitalstruktur oder Insiderstimmung über die übliche Vorstandskomponente hinaus.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Taylor Colleen

(Last) (First) (Middle)
1000 LOWES BOULEVARD

(Street)
MOORESVILLE NC 28117

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
LOWES COMPANIES INC [ LOW ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Phantom Stock(1) (2) 06/30/2025 A 112.679 (2) (2) Common Stock 112.679 $221.87 1,093.537(3) D
Explanation of Responses:
1. Represents the credit of deferred compensation to the Reporting Person's deferred stock account under the Issuer's Directors' Deferred Compensation Plan.
2. Each share of phantom stock is the economic equivalent of one share of common stock. The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of the Issuer.
3. Includes the credit of dividends to the Reporting Person's deferred stock account under the Issuer's Directors' Deferred Compensation Plan.
Remarks:
By: /s/ Sandra Felton by power of attorney for: Colleen Taylor 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many UnitedHealth Group shares did Paul R. Garcia acquire on 07/01/2025?

He received 96 shares of common stock and 173 deferred stock units as part of quarterly board compensation.

What is Paul R. Garcia’s total direct ownership in UNH after the transaction?

Following the award, he directly holds 2,750 common shares of UnitedHealth Group.

Are the deferred stock units (DSUs) immediately vested?

Yes. The DSUs vest immediately but must be held until the director’s service on the board ends.

Did the filing disclose any insider sales or derivative transactions?

No. The Form 4 reports only acquisitions of stock and DSUs; no sales or derivative activity were reported.

Does this Form 4 filing affect UnitedHealth Group’s share count?

No. The awards are sourced from the company’s existing equity compensation plan and do not materially alter the total shares outstanding.
Lowes Companies

NYSE:LOW

LOW Rankings

LOW Latest News

LOW Latest SEC Filings

LOW Stock Data

127.95B
559.70M
0.11%
77.96%
1.31%
Home Improvement Retail
Retail-lumber & Other Building Materials Dealers
Link
United States
MOORESVILLE